|
Match
|
Document |
Document Title |
|
|
US20090286715 |
Pharmaceutical Composition
A pharmaceutical composition comprising: (A) a continuous liquid phase; (B) liquid droplets dispersed in said continuous phase; (C) a pharmaceutically-active compound; (D) an enhancer as described...
|
|
|
US20090270438 |
Novel compositions and formulations
There is provided according to the invention a non-pressurised pharmaceutical liquid solution spray composition comprising: (i) buprenorphine; and a solvent comprising ethanol which composition is...
|
|
|
US20090264454 |
COMBINED HYDROCODONE AND ANALGESIC FORMULATION AND METHOD
The present invention is directed to co-administration of hydrocodone and a second analgesic agent for the treatment of pain. A pharmaceutical composition suitable for the co-administration...
|
|
|
US20090264385 |
STABILIZED COMPOSITIONS CONTAINING ALKALINE LABILE DRUGS
A stabilized bioadhesive composition containing an alkaline labile drug and a method for its preparation are provided. In one aspect, the composition is a hot-melt extruded (HME) composition...
|
|
|
US20090263476 |
Composition of Rapid Disintegrating Direct Compression Buccal Tablet
A composition of a rapidly disintegrating buccal dosage form containing a drug, at least one non-effervescent base such as an alkali metal or alkaline earth metal oxide or hydroxide, and a...
|
|
|
US20090263441 |
DRUG DEPOTS HAVING DIFFREENT RELEASE PROFILES FOR REDUCING, PREVENTING OR TREATING PAIN AND INFLAMMATION
Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a...
|
|
|
US20090258891 |
Macrocyclic Compounds As Antiviral Agents
The present invention relates to macrocyclic compounds of formula (I): wherein W, n, R 1 , R a , R b , R 3 , R 4 , M, Z, ring A and ring B are defined herein, and pharmaceutically acceptable salts...
|
|
|
US20090253730 |
Method and composition for deterring abuse of opioid containing dosage forms
This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
|
|
|
US20090253729 |
Analgesic Agent
A pharmaceutical preparation useful for alleviating or treating a pain, e.g., a chronic pain (particularly, a neuropathic pain) is provided. The pharmaceutical preparation contains (a) a propionic...
|
|
|
US20090253728 |
Methods and Compositions for Treating Nociceptive Pain
The present invention provides methods and compositions useful for the treatment and prevention of pain.
|
|
|
US20090247562 |
LARGE SUBSTITUENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF
8-Substituted-2,6-methano-3-benzazocines of general structure
are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.
|
|
|
US20090239841 |
Diaryl Ureas as CB1 Antagonists
Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the...
|
|
|
US20090238868 |
ABUSE-RESISTANT ORAL DOSAGE FORMS AND METHOD OF USE THEREOF
An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but...
|
|
|
US20090233841 |
ANALGESIC CONJUGATES
The present invention relates generally to analgesic compounds having a mu opioid receptor agonist linked to a delta opioid receptor antagonist, and to methods for producing analgesia using such...
|
|
|
US20090227615 |
Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
|
|
|
US20090221621 |
Methods of Reducing Alcohol-Induced Dose Dumping for Opioid Sustained Release Oral Dosage Forms
Disclosed are methods of sustained release administration of opioids, including but not limited to hydromorphone and oxycodone, that exhibit improved properties with respect to co-ingestion with...
|
|
|
US20090220450 |
Methods and compositions for wound healing
Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and/or improvement of wound healing and/or tissue repair.
|
|
|
US20090220435 |
TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS
Compounds and components including sequences for mucosal epithelial transport of an active agent are given. Tight junction modulating peptide components are described for use in transport and...
|
|
|
US20090215809 |
CRYSTALLINE FORM OF A (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUG AND METHODS OF USE
A crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug and methods of preparing a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug, and methods of using a crystalline form...
|
|
|
US20090215808 |
Oral pharmaceutical dosage forms
Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.
|
|
|
US20090214650 |
Methods of Treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
The current invention provides methods of treating alcohol related disorders by providing a sustained release oral drug dosage form comprising a plurality of solid state drugs i.e., baclofen and...
|
|
|
US20090209570 |
6-Aminomorphinane Derivatives, Method for the Production and Use Thereof
This invention relates to compounds of the formula (I).
|
|
|
US20090209569 |
SELECTIVE OPIOID COMPOUNDS
The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which relates to morphinan compounds useful as μ, δ, and/or κ...
|
|
|
US20090208540 |
IMPLANTABLE DEVICE FOR THE DELIVERY OF NALTREXONE AND METHODS OF USE THEREOF
This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver naltrexone and formulations thereof at a constant rate for an extended period of time. The...
|
|
|
US20090203723 |
6,7-unsaturated-7-carbamoyl substituted morphinan derivative
A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I):
wherein R 1 and R 2 are each...
|
|
|
US20090203722 |
Novel compositions and methods for enhancing potency or reducing adverse side effects of opiold agonists
The invention generally relates to novel compositions and methods with an opioid agonist and an opioid antagonist to differentially dose a human subject so as to either enhance analgesic potency...
|
|
|
US20090202633 |
Extended release formulations of guaifenesin
The present invention relates to extended release formulations comprising expectorant. More particularly, the present invention relates to extended release formulations comprising guaifenesin. The...
|
|
|
US20090202629 |
Controlled release hydrocodone formulations
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,...
|
|
|
US20090197905 |
QUATERNARY OPIOID CARBOXAMIDES
Compounds of formulas:
are disclosed. The compounds are useful for ameliorating the side effects of therapeutic opiates.
|
|
|
US20090196824 |
TREATMENT OF SEQUELAE OF PSYCHIATRIC DISORDERS
In general, the invention provides methods and compositions for treating sequela of weight gain or pain insensitivity, e.g., in a subject suffering from a psychiatric disorder, such as...
|
|
|
US20090192183 |
Oxymorphone Controlled Release Formulations
The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24...
|
|
|
US20090192095 |
AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS
The present invention relates to methods for reducing gastrointestinal side effects in a subject, the gastrointestinal side effects being associated with the administration of an opioid analgesic....
|
|
|
US20090186832 |
AMINO ACID PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF
Prodrugs of meptazinol and other phenolic analgesics exhibiting low oral bioavailability with amino acids or lower peptides, pharmaceutical compositions containing such prodrugs and a method for...
|
|
|
US20090181999 |
USE OF COMPOSITIONS CONTAINING KAPPA-OPIOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DISSOCIATIVE DISORDERS
The invention relates to the use of a composition comprising kappa opioid receptor antagonists for producing a drug for the treatment of dissociative disorders in humans.
|
|
|
US20090181998 |
OPIOID RECEPTOR SUBTYPE-SELECTIVE AGENTS
Opioid receptor compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a condition mediated by an opioid receptor by administering an effective...
|
|
|
US20090181954 |
Patches, formulations, and associated methods for transdermal delivery of alprazolam and other drugs
The present invention is drawn to transdermal drug formulations, transdermal patches incorporating such formulations, as well as associated methods. The formulations can include about 0.3 wt % to...
|
|
|
US20090175939 |
PHARMACEUTICAL COMPOSITIONS
Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.
|
|
|
US20090175933 |
PREPARATION FOR THE TREATMENT OF DIARRHOEA
A preparation for the treatment of diarrhoea comprising a bulking agent and an anti-diarrhoeal agent wherein the anti-diarrhoeal agent is provided in the form of an anti-motility agent.
|
|
|
US20090175882 |
METHODS AND COMPOSITIONS FOR TREATING HYPERALGESIA
This invention provides compounds which specifically inhibit TRPA1 but not other members of the thermoTRP ion channel family. Also provided in the invention are methods of using TRPA1-specific...
|
|
|
US20090170888 |
Antipruritic Agent for Pruritus Caused by Multiple Sclerosis
An antipruritic against pruritus caused by multiple sclerosis is disclosed. The antipruritic comprises as an effective ingredient an κ opioid receptor agonist compound having a 4,5-epoxymorphinan...
|
|
|
US20090169626 |
TAMPER RESISTANT DOSAGE FORMS
Tamper resistant controlled release formulations.
|
|
|
US20090162451 |
PHARMACEUTICAL COMPOSITIONS
Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one...
|
|
|
US20090162450 |
PHARMACEUTICAL COMPOSITION
Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one...
|
|
|
US20090162421 |
DRUGS AS WELL AS THEIR PRODUCTION AND USE IN THE TREATMENT OF PAIN-ASSOCIATED NEUROPATHIES
The present invention relates to the use of tarenflurbil and/or a pharmaceutically tolerable salt or derivative thereof in enantiomerically-pure and/or essentially enantiomerically-pure form or a...
|
|
|
US20090162407 |
PROCESS FOR PREPARING MICROPARTICLES HAVING A LOW RESIDUAL SOLVENT VOLUME
The disclosed processes for forming microparticles utilize low volumes of processing water while still providing microparticles having low residual solvent levels. The processes are adaptable to...
|
|
|
US20090156581 |
Aminergic pharmaceutical compositions and methods
Pharmaceutical compositions and method using aminergic compounds and complement compounds. Compositions are provided comprising: (a) a subefficacious amount of a non-adrenergic aminergic compound...
|
|
|
US20090155235 |
AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN
The invention describes combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid. Judicious choice of system components, which differ at least 2-times to...
|
|
|
US20090143417 |
METHODS OF TREATING PAIN
The present invention is directed to methods and compositions for inducing, promoting or otherwise facilitating pain relief. More particularly the present invention discloses the combination of a...
|
|
|
US20090137618 |
PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS
Pro-drugs containing an electron withdrawing substituent, as defined in the specification, are useful in a method for providing a patient with post administration-activated, controlled release of a...
|
|
|
US20090124650 |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician of the...
|